This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.

Condition	Treatment or Intervention	Phase
Gastrointestinal Cancer	Drug: AMG 706	Phase II

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Subjects must have advanced gastrointestinal stromal tumors
• Subjects must have documented treatment with imatinib mesylate (Gleevec®) at least 600 mg daily for at least 2 months, but the disease has progressed on this treatment

Exclusion Criteria:

• No previous exposure to AMG 706 or other tyrosine kinase inhibitors of c-kit (except imatinib mesylate) or VEGF (vascular endothelial growth factor) type (e.g., SU11248, PTK787) or anti-VEGF antibody (Avastin®)

Amgen Call Center      866-572-6436 

Arizona
      Research Site, Tucson,  Arizona,  United States; Recruiting
California
      Research Site, Los Angeles,  California,  United States; Recruiting
      Research Site, San Francisco,  California,  United States; Recruiting
      Research Site, Santa Monica,  California,  United States; Recruiting
Colorado
      Research Site, Aurora,  Colorado,  United States; Recruiting
District of Columbia
      Research Site, Washington,  District of Columbia,  United States; Recruiting
Illinois
      Research Site, Chicago,  Illinois,  United States; Recruiting
Indiana
      Research Site, Indianapolis,  Indiana,  United States; Recruiting
Michigan
      Research Site, Ann Arbor,  Michigan,  United States; Recruiting
New York
      Research Site, New York,  New York,  United States; Recruiting
Pennsylvania
      Research Site, Philadelphia,  Pennsylvania,  United States; Recruiting

Study ID Numbers:  20040110
Record last reviewed:  February 2005
Last Updated:  February 14, 2005
Record first received:  August 18, 2004
ClinicalTrials.gov Identifier:  NCT00089960
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08